Dana-Farber deal highlights a surprising trend; an endocrinologist on how the Wegovy shortage affects patient care

Taking stock of the drug industry, from the lab to the medicine chest

September 15, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Craig F. Walker/The Boston Globe STAT+ | Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue Medical care is moving outpatient, but Dana-Farber is building a new cancer center. Why? CAR-T therapies are delivered in hospitals. By Tara Bannow Opinion: How the Wegovy shortage is making life impossible for my patients — and for me As an endocrinologist treating metabolic diseases, I feel the Wegovy shortage forces me to literally weigh one patient against another. By Jody Dushay STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Adobe Randomized controlled trials are the 'gold standard' of research — but a difficult fit for trans care Trans health experts say it's time to rethink demands for further research in order to justify the provision of gender-affirming care. By Theresa Gaffney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser